133 related articles for article (PubMed ID: 36801634)
21. CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus.
Zhao K; Ma L; Feng L; Huang Z; Meng X; Yu J
Front Mol Biosci; 2020; 7():608404. PubMed ID: 33490104
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of TIGIT and KLRG1 correlates with impaired CD56
Nie Y; Liu D; Yang W; Li Y; Zhang L; Cheng X; Chen R; Yuan B; Zhang G; Wang H
Virol J; 2022 Apr; 19(1):68. PubMed ID: 35413989
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of negative conversion of high-risk Human Papillomavirus DNA after treatment in Cervical Cancer patients.
Chen Q; Shi R; Liu Z; Shi Z; Gu K; Chen J; He Y; Li Y; Wu J; Ji S; Zhou J; Zhu J
J Cancer; 2020; 11(20):5911-5917. PubMed ID: 32922533
[No Abstract] [Full Text] [Related]
24. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
25. TIGIT as a Novel Prognostic Marker for Immune Infiltration in Invasive Breast Cancer.
Guo C; Luo Z; Ismtula D; Bi X; Kong H; Wang Y; Yang Z; Mao X
Comb Chem High Throughput Screen; 2023; 26(3):639-651. PubMed ID: 35770416
[TBL] [Abstract][Full Text] [Related]
26. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
27. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract][Full Text] [Related]
28. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers.
Hosseinkhani N; Shadbad MA; Asghari Jafarabadi M; Karim Ahangar N; Asadzadeh Z; Mohammadi SM; Lotfinejad P; Alizadeh N; Brunetti O; Fasano R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638729
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC).
Stolnicu S; Hoang L; Chiu D; Hanko-Bauer O; Terinte C; Pesci A; Aviel-Ronen S; Kiyokawa T; Alvarado-Cabrero I; Oliva E; Park KJ; Abu-Rustum NR; Soslow RA
Am J Surg Pathol; 2019 Apr; 43(4):466-474. PubMed ID: 30720532
[TBL] [Abstract][Full Text] [Related]
30. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).
Sun Y; Luo J; Chen Y; Cui J; Lei Y; Cui Y; Jiang N; Jiang W; Chen L; Chen Y; Kuang Y; Tang K; Ke Z
Int Immunopharmacol; 2020 Mar; 80():106198. PubMed ID: 31954274
[TBL] [Abstract][Full Text] [Related]
31. Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma.
Zhang Z; Li M; Wang J; Liu M; Chen H; Lou Y; Wang Y; Sun Q; Zhu D; Li P; Bi Y
Endocr Relat Cancer; 2022 May; 29(7):403-413. PubMed ID: 35521773
[TBL] [Abstract][Full Text] [Related]
32. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.
McAlpine JN; Leung SCY; Cheng A; Miller D; Talhouk A; Gilks CB; Karnezis AN
Histopathology; 2017 Aug; 71(2):238-246. PubMed ID: 28257152
[TBL] [Abstract][Full Text] [Related]
34. Survival‑related DLEU1 is associated with HPV infection status and serves as a biomarker in HPV‑infected cervical cancer.
Dong A; Xu B; Wang Z; Miao X
Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35014679
[TBL] [Abstract][Full Text] [Related]
35. [Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].
Zuo MN; DU YQ; Yu LP; Dai X; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):636-643. PubMed ID: 35950385
[TBL] [Abstract][Full Text] [Related]
36. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
37. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
Stålhammar G; Seregard S; Grossniklaus HE
Cancer Med; 2019 Jun; 8(6):2784-2792. PubMed ID: 30993893
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral TIGIT
Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
[TBL] [Abstract][Full Text] [Related]
39. Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.
Huang S; Zhao Y; Liao P; Wang J; Li Z; Tan J; Zha X; Chen S; Li Y; Zhong L
Front Oncol; 2022; 12():1014904. PubMed ID: 36439426
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes--correlation with clinico-pathological parameters and prognostic significance.
Pilch H; Günzel S; Schäffer U; Tanner B; Brockerhoff P; Maeurer M; Höckel M; Hommel G; Knapstein PG
Zentralbl Gynakol; 2001 Feb; 123(2):91-101. PubMed ID: 11265139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
